Impact of Physical Activity on Oxidative Stress Markers in Patients with Metastatic Breast Cancer
Table 4
Antioxidant, prooxidant enzymes, and oxidative stress markers at baseline between patients with unfavorable and favorable clinical outcomes, ABLE Trial, 2016-2018.
Biomarkers
Favorable outcomes ()
Unfavorable outcomes ()
a
Antioxidant enzymes
CAT (μmol.min-1.L-1), mean (SD)
34.32 (18.94)
33.55 (18.54)
0.87
GPX (μmol.min-1.L-1), mean (SD)
70.55 (25.48)
63.17 (20.19)
0.22
SOD (μmol.min-1.L-1), mean (SD)
9.62 (4.20)
7.69 (4.56)
0.28
Prooxidant enzymes
NADPH oxidase leucocytes (μmol.min-1.mg (prot)-1), mean (SD)
0.22 (0.05)
0.24 (0.07)
0.40
MPO plasma (μmol.min-1.L-1), mean (SD)
111.59 (57.83)
122.41 (60.72)
0.37
MPO leucocytes (μmol.min-1.mg(prot)-1), mean (SD)
15.78 (4.22)
16.31 (5.09)
0.58
Oxidative stress markers
MDA (μmol.L-1), mean (SD)
11.04 (2.96)
13.33 (3.66)
0.04
8-OHdG (μg.L-1), mean (SD)
17.67 (18.99)
15.33 (15.71)
0.55
AOPP (μmol.L-1), mean (SD)
88.07 (59.63)
48.31 (13.34)
0.008
aKruskal-Wallis test. CAT: catalase; SOD: superoxide dismutase; NADPH: nicotinamide adenine dinucleotide phosphate; MPO: myeloperoxidase; 8-OhdG: 8-hydroxydeoxyguanosine; AOPP: advanced oxidation protein products; MDA: malondialdehyde; GPX: glutathione peroxidase. Unfavorable clinical outcomes: RECIST metastatic progression or death during the intervention period. Favorable clinical outcomes: no RECIST metastatic progression and no death during the intervention period.
